<DOC>
	<DOCNO>NCT00962988</DOCNO>
	<brief_summary>Research Aims The aim research study determine whether cost-free smoking cessation pharmacotherapy : 1 . Helps smoker Transient Ischemic Attack ( TIA ) stroke quit smoking long-term , compare simply provide prescription medication ; 2 . Is cost-effective alternative provide prescription medication high risk population . Hypotheses Tested The hypothesis test include follow : 1 . The CO-validated continuous abstinence rate week 26 52 follow target quit date least 10 % high cost-free smoking cessation pharmacotherapy intervention group compare prescription usual care group ; 2 . Cost-free smoking cessation pharmacotherapy great cost-effectiveness ( i.e. , cost/quit ) provide prescription .</brief_summary>
	<brief_title>Efficacy Cost-Effectiveness Cost-free Pharmacotherapy Smoking Cessation High-risk Smokers With Cerebrovascular Disease</brief_title>
	<detailed_description>Smokers Transient Ischemic Attack ( TIA ) stroke attend Stroke Prevention Clinic willing quit smoking randomly assign ( 1:1 ) either prescription ( PO ) usual care group cost-free ( CF ) pharmacotherapy experimental group . Participants assign prescription usual care group ask prescription smoke cessation pharmacotherapy fill cost local community pharmacy . Participants assign cost-free pharmacotherapy group provide 12-week supply NRT , 12-week supply bupropion varenicline . The pharmacotherapy provide research nurse patient immediately . All participant receive identical advice regard smoke attend neurologist , nurse counsel smoke cessation , follow-up track telephone-based support 26 week target quit date . Non-treatment follow-up continue week 52 target quit date .</detailed_description>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1 . Patient current daily smoker ( one cigarette per day month precede visit Stroke Prevention Clinic ) 2 . Patient diagnose TIA stroke point time 3 . Patient able , opinion neurologist , comprehend participate smoking cessation intervention 4 . Patient 18 year age old 5 . Patient willing set quit date 6 . Patient willing travel study centre followup visit 7 . Patient willing provide inform consent 1 . Patient unable understand English French 2 . Patient willing use pharmacotherapy quit 3 . Patient use smoke cessation medication 6 week directly prior clinic visit hospital admission . 4 . Patient pregnant , lactate plan become pregnant study period 5 . Patient contraindication ( ) follow smoke cessation medication : Nicotine replacement therapy ( allergy adhesive , serious cardiac arrhythmia ( e.g. , tachycardia ) , vasospastic disease ( e.g. , Buerger 's disease , Prinzmetal 's variant angina ) Bupropion ( history seizure disorder head trauma ; presently take Wellbutrin ; previous reaction bupropion/Zyban/Wellbutrin ; preexist current eating disorder ; take antidepressant , antipsychotic , corticosteroid , MAO inhibitor , theophylline , cocaine diet pill ; take quinalone antibiotic ( e.g. , ciprofloxacin , levoflozacin ) ; currently use oral hypoglycemic product insulin ; severe hepatic impairment ; CNS tumour ; Varenicline ( renal failure ; use cimetidine ; previous reaction varenicline )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Cerebrovascular disease</keyword>
	<keyword>stroke</keyword>
	<keyword>Transient Ischemic Attack</keyword>
	<keyword>smoke cessation</keyword>
	<keyword>Pharmacotherapy</keyword>
</DOC>